Ascentage Pharma to Participate in Four Upcoming Investor Conferences
Management is set to appear in fireside chats, company presentations, and one-on-one meetings at four September 2026 investor conferences in New York.
Rhea-AI Summary
Ascentage Pharma (AAPG) will participate in four investor conferences in New York in September 2026, including events hosted by Citi, H.C. Wainwright, Deutsche Bank, and Bernstein. Management will join fireside chats, company presentations, and one-on-one investor meetings across multiple dates and venues.
Positive
- None.
Negative
- None.
News Market Reaction – AAPG
In the Sep 2 session, AAPG gained 4.74%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management will participate in four upcoming investor conferences in New York, New York.
Citi’s 2026 Biopharma Back to School Conference
Format: Fireside chat and one-on-one investor meetings
Date and Time: Wednesday, September 9, 2026, 4:20 p.m. to 4:55 p.m. ET
Location: JW Marriott Essex House, 160 Central Park South, New York, NY
H.C. Wainwright 28th Annual Global Investment Conference
Format: Company presentation and one-on-one investor meetings
Date and Time: Monday, September 14, 2026, 9:00 a.m. to 9:30 a.m. ET
Location: Lotte New York Palace Hotel, 455 Madison Avenue, New York, NY
Deutsche Bank 2026 Healthcare Summit
Format: Company presentation and one-on-one investor meetings
Date: Wednesday, September 16 - Thursday, September 17, 2026
Location: Deutsche Bank Center, One Columbus Circle, New York, NY
Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum
Format: Company presentation and one-on-one investor meetings
Date: Wednesday, September 23 - Thursday, September 24, 2026
Location: New York, NY
Investors interested in scheduling a meeting with the Ascentage Pharma management team should contact their conference representative.
About Ascentage Pharma
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.
The Company’s first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA- and EMA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as FDA- and EMA-cleared registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.
The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA- and EMA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA- and EMA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company’s ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this press release do not constitute profit forecast by the Company’s management.
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information
Investor Relations:
Sumedh Sunkaraneni
Ascentage Pharma
IR@ascentage.com
+1 (301) 792-6286
Brian Korb
astr partners
brian.korb@astrpartners.com
+1 (917) 653-5122
FAQ
Which investor conferences will Ascentage Pharma (AAPG) attend in September 2026?
Ascentage Pharma will attend Citi’s 2026 Biopharma Back to School Conference, the H.C. Wainwright 28th Annual Global Investment Conference, the Deutsche Bank 2026 Healthcare Summit, and Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum, all held in New York.
When is Ascentage Pharma presenting at Citi’s 2026 Biopharma Back to School Conference (AAPG)?
At Citi’s 2026 Biopharma Back to School Conference, Ascentage Pharma will participate in a fireside chat and one-on-one investor meetings on Wednesday, September 9, 2026, from 4:20 p.m. to 4:55 p.m. ET at the JW Marriott Essex House in New York.
What is the date and time of Ascentage Pharma’s session at the H.C. Wainwright 28th Annual Global Investment Conference (AAPG)?
At the H.C. Wainwright 28th Annual Global Investment Conference, Ascentage Pharma will give a company presentation and hold one-on-one investor meetings on Monday, September 14, 2026, from 9:00 a.m. to 9:30 a.m. ET at the Lotte New York Palace Hotel.
When will Ascentage Pharma join the Deutsche Bank 2026 Healthcare Summit (AAPG)?
Ascentage Pharma will take part in the Deutsche Bank 2026 Healthcare Summit with a company presentation and one-on-one investor meetings on Wednesday, September 16 to Thursday, September 17, 2026 at Deutsche Bank Center, One Columbus Circle, New York.
What are the dates for Ascentage Pharma at the Bernstein Insights 3rd Annual Healthcare Forum (AAPG)?
Ascentage Pharma will present and hold one-on-one investor meetings at the Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum on Wednesday, September 23 to Thursday, September 24, 2026 in New York, New York.
How can investors schedule one-on-one meetings with Ascentage Pharma (AAPG) at these conferences?
Investors who wish to schedule a one-on-one meeting with Ascentage Pharma’s management at any of the four New York conferences should contact their respective conference representative to arrange a meeting time.